COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #78
Source   PDF   Share   Tweet
See all 181 studies
7/11
Negative
Late treatment study
Lecronier et al., Critical Care, 24:418, 2020, doi:10.1186/s13054-020-03117-9 (Peer Reviewed)
Comparison of hydroxych loroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis
Retrospective 80 ICU patients, 22 SOC, 20 lopinavir/ritonavir, 38 HC Q. 28 day mortality 24% (HC Q) versus 41% (SOC), a 41% decrease, but not statistically significant due to very small sample sizes. No statistically significant differences found for treatment escalation, ventilator-free days, viral load, or mortality. Authors consider treatment escalation more important than mortality, for unknown reasons.
death, ↓42.0%, p=0.24, HCQ vs. control
treatment escalation, ↓6.0%, p=0.73, HCQ vs. control
no virological cure, ↓15.0%, p=0.61, risk of viral+ at day 7, HCQ vs. control
Source   PDF   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.
Submit